RJA
CRBP icon

Raymond James & Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

Raymond James & Associates’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-589
Closed -$35K – 4113
2021
Q1 		$35K Hold
589
– – ﹤0.01% 3879
2020
Q4 		$22K Sell
589
-798
-58% -$29.8K ﹤0.01% 3681
2020
Q3 		$75K Sell
1,387
-516
-27% -$93.4K ﹤0.01% 3411
2020
Q2 		$479K Buy
1,903
+583
+44% +$118K ﹤0.01% 2612
2020
Q1 		$207K Sell
1,320
-733
-36% -$124K ﹤0.01% 3022
2019
Q4 		$336K Sell
2,053
-107
-5% -$15.8K ﹤0.01% 3018
2019
Q3 		$316K Sell
2,160
-601
-22% -$105K ﹤0.01% 2974
2019
Q2 		$574K Buy
2,761
+542
+24% +$116K ﹤0.01% 2559
2019
Q1 		$463K Sell
2,219
-331
-13% -$73K ﹤0.01% 2711
2018
Q4 		$447K Buy
2,550
+1,165
+84% +$233K ﹤0.01% 2614
2018
Q3 		$314K Buy
1,385
+765
+123% +$124K ﹤0.01% 2994
2018
Q2 		$94K Buy
620
+90
+17% +$16.4K ﹤0.01% 3407
2018
Q1 		$97K Buy
+530
New +$119K ﹤0.01% 3270
2017
Q2 		– Sell
-4,194
Closed -$1.04M – 3352
2017
Q1 		$1.04M Sell
4,194
-462
-10% -$113K ﹤0.01% 1958
2016
Q4 		$1.18M Buy
+4,656
New +$1.07M ﹤0.01% 1833
2016
Q2 		– Sell
-2,815
Closed -$153K – 3031
2016
Q1 		$153K Buy
+2,815
New +$124K ﹤0.01% 2639

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Raymond James & Associates's CRBP Position: Q2 2021 in Review

Raymond James & Associates sold out of Corbus Pharmaceuticals (CRBP) in Q2 2021, closing a stake of 589 shares — an estimated $35K sold.

Raymond James & Associates first reported a position in CRBP in Q1 2016 and held it in 16 quarters. The position peaked at $1.18M in Q4 2016. 98 funds tracked by Wall St. Rank hold CRBP as of Q2 2021.

  • Raymond James & Associates reported no remaining Corbus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 589 Corbus Pharmaceuticals shares in Q2 2021, an estimated $35K.
  • Raymond James & Associates first reported a position in Corbus Pharmaceuticals in Q1 2016 and held it in 16 quarters.
  • Raymond James & Associates's Corbus Pharmaceuticals position peaked at $1.18M in Q4 2016.
  • 98 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.